Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
AUTOLOGOUS CD34+ CELLS ENCODING .BETA.A-T87Q-GLOBIN GENE Transfusion-dependent Beta-Thalassemia	Editas Medicine, Inc.	P1/2	CCC (55)
cd22 car-transduced t cells Childhood Acute Lymphoblastic Leukemia	Sumithira Vasu	P1/2	CCC (55)
Chimeric Antigen Receptor Modified T Cells Infusion Advanced Hepatocellular Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (55)
Autologous monocytes Glioblastoma	Aivita Biomedical, Inc.	P3	CCC (54)
Cart-19 Cells Diffuse Large B-Cell Lymphoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P3	CCC (54)
Jcar017 (Lisocabtagene Maraleucel) Large B-Cell Lymphoma	Lyell Immunopharma, Inc.	P3	CCC (54)
Rondecabtagene Autoleucel B-Cell Non-Hodgkin Lymphoma	Lyell Immunopharma, Inc.	P3	CCC (54)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Alzheimer Disease	NKGen Biotech, Inc.	P2	CCC (54)
Anti-Bcma Car-T Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (54)
Bcma-Gprc5D Car-T Cells Plasma Cell Myeloma	Donghua Zhang	P2	CCC (54)
Hpc, Cord Blood Leukemia	Memorial Sloan Kettering Cancer Center	P2	CCC (54)
Hpc, Cord Blood Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (54)
Treg Cells Myelodysplastic Syndrome	Masonic Cancer Center, University of Minnesota	P2	CCC (54)
Adipose Derived Stem Cell Stroke Disorder	University Hospital, Grenoble	P2/3	CCC (54)
Allogeneic Bone Marrow-Derived Mscs Lumbar Disk Degenerative Disorder	University Hospital, Montpellier	P2/3	CCC (54)
Allogeneic Cd8+ Leukemia-Associated Antigens Specific T Cells Nexi-001 Myelodysplastic Syndrome	City of Hope Medical Center	P1/2	CCC (54)
Anti-Bcma Car-Nk Cells Plasma Cell Myeloma	Shahid Beheshti University of Medical Sciences	P1/2	CCC (54)
Anti-Bcma Car T Cells Plasma Cell Myeloma	Hebei Senlang Biotechnology Inc., Ltd.	P1/2	CCC (54)
Anti-Bcma Car T Cells Multiple Myeloma Refractory	Hebei Senlang Biotechnology Inc., Ltd.	P1/2	CCC (54)
AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING OF AN ANTI-CD19 SPECIFIC SCFV, A CD8.ALPHA. STALK, TRANSMEMBRANE DOMAIN AND ANCHOR, A 41BB ENDODOMAIN AND A CD3 ZETA ENDODOMAIN, UNDER THE CONTROL OF A HUMAN PGK1 PROMOTER AND A MODIFIED WOODCHUCK POST TRANSCRIPTIONAL RESPONSE ELEMENT. THE VECTOR GENOME ALSO CONTAINS A 5' TERMINAL CMV ENHANCER/PROMOTER, A .PSI. PACKAGING SIGNAL, A REV RESPONSE ELEMENT (RRE) AND A CENTRAL POLYPURINE TRACT (CPPT) B-Cell Acute Lymphoblastic Leukemia	Autolus Limited	P1/2	CCC (54)
cd5-targeted car-t cells T-Cell Non-Hodgkin Lymphoma	Beijing GoBroad Hospital	P1/2	CCC (54)
cd7.car/28zeta car t cells T-Lymphoblastic Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (54)
cd7-specific car gene-engineered t cells Extranodal Nasal NK/T Cell Lymphoma	Shenzhen Geno-Immune Medical Institute	P1/2	CCC (54)
cd7-specific car gene-engineered t cells T-Lymphoblastic Lymphoma	Shenzhen Geno-Immune Medical Institute	P1/2	CCC (54)
Chimeric Antigen Receptor Modified T Cells Infusion Immune System Diseases	UNC Lineberger Comprehensive Cancer Center	P1/2	CCC (54)

Showing 201 to 225 of 3,774 assets

PreviousPage 9 of 151Next